



## Press Release

Montrouge, April 3, 2018

# DBV Technologies to Attend the 11<sup>th</sup> Kempen Life Sciences Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will host investor meetings during the 11<sup>th</sup> Kempen Life Sciences Conference on Wednesday, April 18, 2018 at the Kempen & Co offices in Amsterdam, Netherlands.

### About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: [www.dbv-technologies.com](http://www.dbv-technologies.com)

### DBV Investor Relations Contact

**Sara Blum Sherman**

Senior Director, Investor Relations & Strategy

+1 212-271-0740

[sara.sherman@dbv-technologies.com](mailto:sara.sherman@dbv-technologies.com)

### DBV Media Contact

**Roberta Di Giorgio**

Senior Director, Corporate Communications

+1 917-612-2861

[roberta.digiorgio@dbv-technologies.com](mailto:roberta.digiorgio@dbv-technologies.com)